EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

SGLT1 inhibition in cystic fibrosis: From preclinical evidence to clinical potential

Xiubin Liang, Yang Liu, Shijing Jia, Kezhong Zhang, Jie Xu

Molecular Therapy Advances · 2026-12 · 34 (4) · 201868

DOI: 10.1016/j.omta.2026.201868 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Xiubin Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School,…. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Heart Lung and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a life-threatening autosomal recessive disease caused by loss-of-function mutations in the CF transmembrane conductance regulator (CFTR) gene. Although highly effective CFTR modulator therapies (HEMT) have transformed outcomes for many individuals, substantial unmet needs remain, and CF-related metabolic diseases are increasingly recognized as an important therapeutic frontier. Emerging evidence, including our recent work in the CF rabbit model, implicate sodium-glucose cotransporters (SGLTs) as key contributors to CF pathophysiology. This review provides an overview of SGLT biology and the therapeutic use of SGLT inhibitors in metabolic diseases. It summarizes preclinical studies of SGLTs in CF, which have shown that SGLT1 is upregulated in CF human airway epithelial cells and across disease-relevant tissues in CF rabbits in a mutation-independent manner, and that pharmacological SGLT blockade with dual SGLT1/2 inhibitors such as sotagliflozin attenuates endoplasmic reticulum (ER) stress, reduces tissue pathology, and improves survival of CF rabbits. This review calls for expanded preclinical research and future clinical trials to evaluate SGLT1-potent inhibitors as adjunctive therapies to CFTR modulators. As a mutation-agnostic, multi-systemic approach, SGLT1 inhibition holds potential for addressing the extrapulmonary and metabolic manifestations of CF.

Schlagwörter

Stichwörter der Autor:innen

CF hepatobiliary involvementCF-related diabetesSGLT inhibitorscystic fibrosissodium-glucose cotransporters

Autor:innen und Institutionen

  • Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Heart Lung and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Liang, X., Liu, Y., Jia, S., Zhang, K., & Xu, J. (2026). SGLT1 inhibition in cystic fibrosis: From preclinical evidence to clinical potential. Molecular Therapy Advances, 34(4), 201868. https://doi.org/10.1016/j.omta.2026.201868

Vancouver

Liang X, Liu Y, Jia S, Zhang K, Xu J. SGLT1 inhibition in cystic fibrosis: From preclinical evidence to clinical potential. Molecular Therapy Advances. 2026;34(4):201868. doi:10.1016/j.omta.2026.201868

BibTeX
@article{Liang2026,
  author = {Liang, Xiubin and Liu, Yang and Jia, Shijing and Zhang, Kezhong and Xu, Jie},
  title = {SGLT1 inhibition in cystic fibrosis: From preclinical evidence to clinical potential},
  journal = {Molecular Therapy Advances},
  year = {2026},
  volume = {34},
  number = {4},
  pages = {201868},
  doi = {10.1016/j.omta.2026.201868}
}
Kostenlos starten →